Media

Check out our latest corporate updates, features in the media, and scientific publications and presentations.

Company Videos

Candel Company Culture
Candel Science Overview
Candel Patient Commitment
Candel Manufacturing

1 2 3 4

Media

Posters & Presentations

2022

2022 Virtual Research & Development Day

Presentation

37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
Patrick Y. Wen, MD

Oral Presentation

Dynamic analyses of tumor microenvironment modulation by CAN-2409 treatment using Kaede photoconvertible transgenic mice
Anne R. Diers, PhD

Poster Presentation
5-minute video

American Society of Clinical Oncology (ASCO) Annual Meeting 2022

First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC
Charu Aggarwal, MD, MPH

Poster Presentation
5-minute video

2021

36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
Patrick Y. Wen, MD
Oral Presentation

36th Annual Meeting of the Society for Neuro-Oncology (SNO)

Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma
Francesca Barone, MD, PhD
Poster Presentation

28th Annual Prostate Cancer Foundation’s Scientific Retreat

Patient experience with intraprostatic injection of CAN-2409 or placebo followed by valacyclovir in a phase 3 clinical trial for localized prostate cancer in combination with standard of care radiation therapy with or without androgen suppression
Laura K. Aguilar, MD
Poster Presentation

Cambridge Healthtech Institute’s 9th Annual Immuno-Oncology Summit

Oncolytic Virus Immunotherapy, Tipping the balance in favor of the immune system to fight cancer
Paul Peter Tak, MD, PhD, FMedSci
Oral Presentation

Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer

Safety and Feasibility of Intraprostatic Injection of CAN-2409 or Placebo followed by Valacyclovir in Patients on Active Surveillance for Prostate Cancer (ULYSSES Trial)
Scott Eggener, MD
Oral Presentation

American Society of Clinical Oncology (ASCO) Annual Meeting 2021

First in human clinical trial with CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma
E. Antonio Chiocca, MD PhD
Oral Presentation

Publications

Rahman et al. The Lancet Oncology (2021)
Leveraging external data in the design and analysis of clinical trials in neuro-oncology
Publication

Predina et al. Molecular Therapy (2020)
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity
Publication

Kieran et al. Neuro-Oncology (2019)
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma
Publication

Aggarwal et al. Molecular Therapy (2018)
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion
Publication

Speranza et al. Neuro-Oncology (2018)
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
Publication

Wheeler et al. Neuro-Oncology (2016)
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
Publication

Aguilar et al. Cancer Immunology, Immunotherapy (2015)
Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma
Publication